相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How long should we treat?
C. Roux et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Global Consensus Statement on Menopausal Hormone Therapy
T. J. de Villiers et al.
CLIMACTERIC (2013)
Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials
JoAnn E. Manson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2013)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy A Randomized Controlled Trial
Andrea Z. LaCroix et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Fracture risk remains reduced one year after discontinuation of risedronate
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
R Prince et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Rapid loss of hip fracture protection after estrogen cessation: Evidence from the national osteoporosis risk assessment
J Yates et al.
OBSTETRICS AND GYNECOLOGY (2004)
Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers
JC Gallagher et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women
SJM Neele et al.
BONE (2002)
分享论文
